Bank Of America Corp Cure Vac N.V. Transaction History

Bank Of America Corp

$1.06 Trillion
Q1 2024

A detailed history of Bank Of America Corp transactions in Cure Vac N.V. stock. As of the latest transaction made, Bank Of America Corp holds 21,939 shares of CVAC stock, worth $80,516. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,939

Previous 19,071 15.04%

Holding current value

$80,516

Previous $80,000 17.5%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.94 - $4.34 $8,431 - $12,447	2,868 Added 15.04%	21,939 $66,000
Q4 2023 Feb 14, 2024	BUY	$3.96 - $6.41 $19,538 - $31,626	4,934 Added 34.9%	19,071 $80,000
Q2 2023 Aug 14, 2023	SELL	$6.69 - $12.25 $951,766 - $1.74 Million	-142,267 Reduced 90.96%	14,137 $147,000
Q1 2023 May 12, 2023	BUY	$6.38 - $12.5 $618,330 - $1.21 Million	96,917 Added 162.92%	156,404 $1.09 Million
Q4 2022 Feb 10, 2023	BUY	$5.75 - $8.5 $276,943 - $409,394	48,164 Added 425.36%	59,487 $358,000

Q3 2022 Nov 14, 2022	SELL	$7.48 - $15.24 $366,901 - $747,537	-49,051 Reduced 81.25%	11,323 $89,000
Q2 2022 Aug 12, 2022	BUY	$13.18 - $19.41 $404,691 - $595,984	30,705 Added 103.49%	60,374 $821,000
Q1 2022 May 16, 2022	SELL	$14.73 - $35.25 $636,571 - $1.52 Million	-43,216 Reduced 59.29%	29,669 $582,000
Q4 2021 Feb 08, 2022	BUY	$33.72 - $48.22 $1.75 Million - $2.5 Million	51,856 Added 246.59%	72,885 $2.5 Million
Q3 2021 Nov 15, 2021	SELL	$49.26 - $74.5 $473,388 - $715,945	-9,610 Reduced 31.37%	21,029 $1.15 Million
Q2 2021 Sep 13, 2021	BUY	$56.91 - $127.53 $1.74 Million - $3.91 Million	30,639 New	30,639 $2.25 Million

Others Institutions Holding CVAC

# of Institutions

Shares Held

15.2M

Call Options Held

31.4K

Put Options Held

137K

View Full List

About CureVac N.V.

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $688M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

More about CVAC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Cure Vac N.V. Transaction History